ESTRO 2021 Abstract Book

S134

ESTRO 2021

posterior eye was 11.4Gy/20.3Gy for photons/protons (population median). The accumulated dose to OARs was robust with no large variations between nominal and accumulated doses (Table 1).

Conclusion Photon and proton plans have different dose benefits for OARs close to and farther from the target. Robustness to anatomical variations was high for both photons and protons, but for proton therapy, strategies to ensure target coverage throughout treatment on an individual basis are needed. Patient selection for proton therapy should be done on patient individual basis. OC-0204 Prompt-gamma-based verification in proton therapy: CNN-based classification of treatment deviations J. Pietsch 1,2 , C. Khamfongkhruea 1,3 , J. Berthold 1,2 , G. Janssens 4 , K. Stützer 1,2 , S. Löck 1,5,6,7 , C. Richter 1,2,5,6,7 1 OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; 2 Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany; 3 Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand; 4 Ion Beam Applications SA, Research, Louvain-la-Neuve, Belgium; 5 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 6 German Cancer Consortium (DKTK), partner site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany; 7 Shared last authorship, -, -, Germany

Purpose or Objective